Vis enkel innførsel

dc.contributor.authorRøsjø, Helge
dc.contributor.authorDahl, Mai Britt
dc.contributor.authorBye, Anja
dc.contributor.authorAndreassen, Johanna
dc.contributor.authorJørgensen, Marit
dc.contributor.authorWisløff, Ulrik
dc.contributor.authorChristensen, Geir Arve
dc.contributor.authorEdvardsen, Thor
dc.contributor.authorOmland, Torbjørn
dc.date.accessioned2015-11-24T09:34:51Z
dc.date.accessioned2015-12-09T14:29:00Z
dc.date.available2015-11-24T09:34:51Z
dc.date.available2015-12-09T14:29:00Z
dc.date.issued2014
dc.identifier.citationPLoS ONE 2014, 9(3)nb_NO
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11250/2367374
dc.description.abstractBackground: Circulating micro-RNAs have been proposed as a novel class of cardiovascular (CV) biomarkers, but whether they meet analytical requirements and provide additional information to establish risk indices have not been established. miR-210 levels are increased in subjects with low VO2 max, which is a recognized risk factor in patients with aortic stenosis (AS), and we hypothesized that circulating miR-210 levels may be increased in patients with AS and associated with a poor prognosis. Methods: We measured circulating miR-210 levels by real-time PCR in 57 patients with moderate to severe AS and in 10 age- and gender-matched healthy controls. The merit of miR-210 as a biomarker was assessed according to established criteria, including by comparing miR-210 levels with NT-proBNP and miR-22 levels, which is another miRNA biomarker candidate. Results: All patients and control subjects had miR-210 levels within the range of detection (Cq<35) and the analytical variability was low. Circulating miR-210 levels were 2.0±0.2 [mean±SEM] fold increased in AS patients compared to controls (p = 0.002), whereas miR-22 levels were not differently expressed in the AS patients (0.12±0.06 fold increase, p = 0.45). The increase in miR-210 levels in AS patients was comparable to the increment in NT-proBNP levels: [AUC] 0.82 (95% CI 0.70–0.90) vs. 0.85 (0.75–0.93), respectively, p = 0.71. During a median follow-up of 1287 days, 15 patients (26%) died. There was a significant association between higher circulating levels of miR-210 and increased mortality during follow-up: hazard ratio [supra- vs. inframedian levels] 3.3 (95% CI 1.1–10.5), p = 0.039. Adjusting for other risk indices in multivariate analysis did not attenuate the prognostic merit of circulating miR-210 levels. Conclusion: Circulating miR-210 levels are increased in patients with AS and provide independent prognostic information to established risk indices. Analytical characteristics were also excellent supporting the potential of micro-RNAs as novel CV biomarkers.nb_NO
dc.language.isoengnb_NO
dc.publisherPublic Library of Sciencenb_NO
dc.titlePrognostic value of circulating microRNA-210 levels in patients with moderate to severe aortic stenosisnb_NO
dc.typeJournal articlenb_NO
dc.typePeer revieweden_GB
dc.date.updated2015-11-24T09:34:51Z
dc.source.volume9nb_NO
dc.source.journalPLoS ONEnb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1371/journal.pone.0091812
dc.identifier.cristin1166683
dc.description.localcode© 2014 Røsjø et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel